IVOIRE STUDY: Efficacy and safety of Oral Drugs treatment in CCRCC: Focus on each therapeutic line and drugs. Results of a prospective multicentric non-randomised study

**Investigator:**

**Observatory:**
- Observatoire dédié au Cancer Bretagne / Pays de la Loire
- http://www.observatoirebcpl.org

**Objectives:**
- Focus on each therapeutic line and drugs.

**Methods:**
- Prospective study with an initial inclusion of 248 patients from 17 centres.
- Patients included between September 2011 and September 2014.
- Patients were included if they had a metastatic RCC and had been treated with a TKI or an everolimus in first line.
- Patients who had not received everolimus in first line were treated with everolimus in the second line.
- Patients who had failed 2nd line treatment were proposed to receive a 3rd line treatment if they could be treated by TKI or mTOR inhibitor.
- Patients who had failed 3rd line treatment were proposed to receive a 4th line treatment.
- Patients who had failed 4th line treatment were proposed to receive a 5th line treatment if they could be treated by TKI or everolimus.

**Key Points:**
- 39% of patients have received a 3rd line treatment.
- 21% of patients have received a 4th line treatment.
- 21% of patients have received a 5th line treatment.

**Conclusion:**
- The study shows the importance of continuing treatment with TKI or everolimus in patients with metastatic RCC.
- The study also highlights the need for further research on the use of new therapeutic agents in the treatment of metastatic RCC.

**Safety:**
- Grade 1 and 4 Toxicities

During 1st and 2nd line:
- 13% of patients presented major toxicity with TKI.
- 14% of patients presented major toxicity with everolimus.
- Toxicity previously described: 10% in first line (Motzer 2007, Escudier 2007)

**Dose delays and discontinuations**
- Reason for dose reduction: 9%
- Reason for treatment discontinuation: 4%

**Clinical benefit (CR + PR + SD):**
- Line 1: 54% for TKI and 51% for everolimus.

**OS:**
- 50 months (95% CI: 46-54).

**Short-term outlook:**
- Optimization of Care: anticipate side-effects and interaction, improve patient’s observance

**Acknowledgments:**
- For private and public hospitals of Bretagne, Pays de la Loire, HST & Basc Normandie for clinicians, CNM and directors.